Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | Venetoclax and ruxolitinib treatment strategies for myeloma

Noopur Raje • 1 Jun 2018
ASCO 2018
Multiple Myeloma Carfilzomib Ruxolitinib Venetoclax

A number of novel treatment strategies for multiple myeloma (MM) are being studied. A few such studies are discussed here by Noopur Raje, MD, of Massachusetts General Hospital Cancer Center, Boston, MA. Prof. Raje covers the use of venetoclax in combination with carfilzomib for relapsed/refractory MM (NCT02899052). She also mentions the combination of low-dose lenalidomide with the JAK inhibitor ruxolitinib (NCT03110822). This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL.

More from Noopur Raje

2:06
Challenges with selecting therapy after failure of frontline treatments in R/R multiple myeloma
Noopur Raje • 29 Sep 2023
2:35
Recommendations for managing infections in patients with myeloma treated with bispecifics
Noopur Raje • 29 Sep 2023
1:13
The role of checkpoint inhibitors in multiple myeloma & future considerations for these agents
Noopur Raje • 29 Sep 2023
2:17
Session highlights: practical aspects of immunotherapy in multiple myeloma
Noopur Raje • 29 Sep 2023

Related Videos

1:15
Using MRD to guide treatment decisions in myeloma
Karthik Ramasamy • 28 Apr 2024
0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals